Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017 (2017), Article ID 1271670, 13 pages
https://doi.org/10.1155/2017/1271670
Research Article

Intramyocardial Injection of Recombinant Adeno-Associated Viral Vector Coexpressing PR39/Adrenomedullin Enhances Angiogenesis and Reduces Apoptosis in a Rat Myocardial Infarction Model

1Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xi’an, China
2Department of Neurology, Baoji City People’s Hospital, Baoji, China
3Department of Physiology, Fourth Military Medical University, Xi’an, China

Correspondence should be addressed to Yuewen Hao; moc.361@reifide_2891 and Lijun Sun; moc.361@ummfjlnus

Received 2 December 2016; Revised 29 January 2017; Accepted 9 February 2017; Published 2 March 2017

Academic Editor: Massimo Collino

Copyright © 2017 Rui An et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. B. Fordyce, B. J. Gersh, G. W. Stone, and C. B. Granger, “Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury,” Trends in Pharmacological Sciences, vol. 36, no. 9, pp. 605–616, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. T. A. Gaziano, “Cardiovascular disease in the developing world and its cost-effective management,” Circulation, vol. 112, no. 23, pp. 3547–3553, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. E. G. Nabel and E. Braunwald, “A tale of coronary artery disease and myocardial infarction,” The New England Journal of Medicine, vol. 366, no. 1, pp. 54–63, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Mozaffarian, E. J. Benjamin, A. S. Go et al., “Heart disease and stroke statistics—2015 update : a report from the American Heart Association,” Circulation, vol. 131, no. 4, pp. e29–e39, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. K. A. A. Fox, P. G. Steg, K. A. Eagle et al., “Decline in rates of death and heart failure in acute coronary syndromes, 1999–2006,” Journal of the American Medical Association, vol. 297, no. 17, pp. 1892–1900, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Bagai, G. D. Dangas, G. W. Stone, and C. B. Granger, “Reperfusion strategies in acute coronary syndromes,” Circulation Research, vol. 114, no. 12, pp. 1918–1928, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. S. D. Fihn, J. M. Gardin, J. Abrams et al., “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease,” Journal of the American College of Cardiology, vol. 60, no. 24, pp. e44–e164, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. C. Scimia, A. M. Gumpert, and W. J. Koch, “Cardiovascular gene therapy for myocardial infarction,” Expert Opinion on Biological Therapy, vol. 14, no. 2, pp. 183–195, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Shi, C. R. Ross, T. L. Leto, and F. Blecha, “PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 12, pp. 6014–6018, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Li, L. F. Brown, R. J. Laham, R. Volk, and M. Simons, “Macrophage-dependent regulation of syndecan gene expression,” Circulation Research, vol. 81, no. 5, pp. 785–796, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Li, M. Post, R. Volk et al., “PR39, a peptide regulator of angiogenesis,” Nature Medicine, vol. 6, pp. 49–55, 2000. View at Google Scholar
  12. J. Wu, C. Parungo, G. Wu et al., “PR39 inhibits apoptosis in hypoxic endothelial cells: role of inhibitor apoptosis protein-2,” Circulation, vol. 109, no. 13, pp. 1660–1667, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Kitamura, K. Kangawa, M. Kawamoto et al., “Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma,” Biochemical and Biophysical Research Communications, vol. 192, no. 2, pp. 553–560, 1993. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Tsuruda, J. Kato, K. Hatakeyama et al., “Antifibrotic effect of adrenomedullin on coronary adventitia in angiotensin II-induced hypertensive rats,” Cardiovascular Research, vol. 65, no. 4, pp. 921–929, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Eto, “A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides,” Peptides, vol. 22, no. 11, pp. 1693–1711, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Nakamura, J. Kato, K. Kitamura et al., “Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats,” Circulation, vol. 110, no. 4, pp. 426–431, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Nishida, T. Sato, M. Miyazaki, and H. Nakaya, “Infarct size limitation by adrenomedullin: protein kinase A but not PI3-kinase is linked to mitochondrial KCa channels,” Cardiovascular Research, vol. 77, no. 2, pp. 398–405, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. H. Looi, K. A. Kane, A. R. McPhaden, and C. L. Wainwright, “Adrenomedullin acts via nitric oxide and peroxynitrite to protect against myocardial ischaemia-induced arrhythmias in anaesthetized rats,” British Journal of Pharmacology, vol. 148, no. 5, pp. 599–609, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Okumura, N. Nagaya, T. Itoh et al., “Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway,” Circulation, vol. 109, no. 2, pp. 242–248, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Sun, Y. Hao, X. Nie, X. Zhang, G. Yang, and Q. Wang, “Construction of PR39 recombinant AAV under control of the HRE promoter and the effect of recombinant AAV on gene therapy of ischemic heart disease,” Experimental and Therapeutic Medicine, vol. 4, no. 5, pp. 811–814, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Sun, Y. Hao, X. Nie et al., “Recombinant AAV-PR39-mediated hypoxia-inducible factor 1α gene expression attenuates myocardial infarction,” International Journal of Molecular Medicine, vol. 33, no. 1, pp. 171–177, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Arnaoutova and H. K. Kleinman, “In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract,” Nature Protocols, vol. 5, no. 4, pp. 628–635, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. R. An, L. Zhao, C. Xi et al., “Melatonin attenuates sepsis-induced cardiac dysfunction via a PI3K/Akt-dependent mechanism,” Basic Research in Cardiology, vol. 111, no. 1, article 8, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Toyoda, T. Sloane Guy, and A. Kashem, “Present status and future perspectives of heart transplantation,” Circulation Journal, vol. 77, no. 5, pp. 1097–1110, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Pascual-Gil, E. Garbayo, P. Díaz-Herráez, F. Prosper, and M. J. Blanco-Prieto, “Heart regeneration after myocardial infarction using synthetic biomaterials,” Journal of Controlled Release, vol. 203, pp. 23–38, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. Y.-H. Chang, L. Ye, W. Cai et al., “Quantitative proteomics reveals differential regulation of protein expression in recipient myocardium after trilineage cardiovascular cell transplantation,” Proteomics, vol. 15, no. 15, pp. 2560–2567, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. S. M. Jay and R. T. Lee, “Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair,” Circulation Research, vol. 113, no. 7, pp. 933–943, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. M. D. Hoggan, N. R. Blacklow, and W. P. Rowe, “Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics,” Proceedings of the National Academy of Sciences of the United States of America, vol. 55, no. 6, pp. 1467–1474, 1966. View at Publisher · View at Google Scholar · View at Scopus
  29. R. W. Atchison, B. C. Casto, and W. M. Hammon, “Adenovirus-associated defective virus particles,” Science, vol. 149, no. 3685, pp. 754–756, 1965. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Zacchigna, L. Zentilin, and M. Giacca, “Adeno-associated virus vectors as therapeutic and investigational tools in the cardiovascular system,” Circulation Research, vol. 114, no. 11, pp. 1827–1846, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. M. J. Post, K. Sato, M. Murakami et al., “Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 290, no. 3, pp. R494–R500, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. H. K. Wong, T. T. Cheung, and B. M. Cheung, “Adrenomedullin and cardiovascular diseases,” JRSM Cardiovascular Disease, vol. 1, no. 5, Article ID cvd.2012.012003, 2012. View at Publisher · View at Google Scholar
  33. B. M. Y. Cheung and F. Tang, “Adrenomedullin: exciting new horizons,” Recent Patents on Endocrine, Metabolic and Immune Drug Discovery, vol. 6, no. 1, pp. 4–17, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. L. C. Cantley, “The phosphoinositide 3-kinase pathway,” Science, vol. 296, no. 5573, pp. 1655–1657, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Fujio, T. Nguyen, D. Wencker, R. N. Kitsis, and K. Walsh, “Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart,” Circulation, vol. 101, no. 6, pp. 660–667, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Hernández-Reséndiz, C. Palma-Flores, S. De Los Santos et al., “Reduction of no-reflow and reperfusion injury with the synthetic 17β-aminoestrogen compound Prolame is associated with PI3K/Akt/eNOS signaling cascade,” Basic research in cardiology, vol. 110, no. 2, article 1, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. A. K. Jonassen, M. N. Sack, O. D. Mjøs, and D. M. Yellon, “Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling,” Circulation Research, vol. 89, no. 12, pp. 1191–1198, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Penna, M. Brancaccio, F. Tullio et al., “Overexpression of the muscle-specific protein, melusin, protects from cardiac ischemia/reperfusion injury,” Basic Research in Cardiology, vol. 109, article 418, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. G. N. Masoud and W. Li, “HIF-1α pathway: role, regulation and intervention for cancer therapy,” Acta Pharmaceutica Sinica B, vol. 5, no. 5, pp. 378–389, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. R. J. Lee, M. L. Springer, W. E. Blanco-Bose, R. Shaw, P. C. Ursell, and H. M. Blau, “VEGF gene delivery to myocardium: deleterious effects of unregulated expression,” Circulation, vol. 102, no. 8, pp. 898–901, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Korpisalo, J. P. Hytnen, J. T. T. Laitinen et al., “Capillary enlargement, not sprouting angiogenesis, determines beneficial therapeutic effects and side effects of angiogenic gene therapy,” European Heart Journal, vol. 32, no. 13, pp. 1664–1672, 2011. View at Publisher · View at Google Scholar · View at Scopus